Interleukin-27 and Autoimmune Disorders: A Compressive Review of Immunological Functions
Authors:
- Esmaeil YazdanpanahEYEsmaeil Yazdanpanah
- Alireza PazokiAlireza Pazoki
- Sepehr DadfarSDSepehr Dadfar
- Mohammad Hosein NematiMNMohammad Hosein Nemati
- Seyed Mohammad Sajad SiadatiSSSeyed Mohammad Sajad Siadati
- Mahdieh TarahomiMTMahdieh Tarahomi
- Niloufar OroojiNONiloufar Orooji
- Dariush HaghmoradDHDariush Haghmorad
- Valentyn OksenychValentyn Oksenych
Open Access
- 22 November 2024
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1489
Abstract
Autoimmune disorders (ADs) pose significant health and economic burdens globally, characterized by the body’s immune system mistakenly attacking its own tissues. While the precise mechanisms driving their development remain elusive, a combination of genetic predisposition(s) and environmental triggers is implicated. Interleukin-27 (IL-27), among numerous cytokines involved, has emerged as a key regulator, exhibiting dual roles in immune modulation. This review delves into the molecular structure and signaling mechanisms of IL-27, highlighting its diverse effects on various immune cells. Additionally, it explores the involvement of IL-27 in autoimmune diseases, such as multiple sclerosis (MS) and rheumatoid arthritis (RA), offering insights into its potential therapeutic implications. Moreover, its involvement in autoimmune diseases like type 1 diabetes (T1D), inflammatory bowel disease (IBD), myasthenia gravis (MG), Sjögren’s syndrome (SS), and Guillain-Barré syndrome (GBS) is multifaceted, with potential diagnostic and therapeutic implications across these conditions. Further research is essential to fully understand IL-27’s mechanisms of action and therapeutic potential in autoimmune diseases.Keywords
Funding Information
- Research Council of Norway Young Talent Investigator (#249774, #13477, #38811, #182355, #270491, #291217, 2017–2021, #2020-02155)
- Liaison Committee for education, research, and innovation in Central Norway (#249774, #13477, #38811, #182355, #270491, #291217, 2017–2021, #2020-02155)
- Norwegian Cancer Society (#249774, #13477, #38811, #182355, #270491, #291217, 2017–2021, #2020-02155)
- Research Council of Norway FRIMEDBIO grants (#249774, #13477, #38811, #182355, #270491, #291217, 2017–2021, #2020-02155)
- Outstanding Academic Fellow Program at NTNU (#249774, #13477, #38811, #182355, #270491, #291217, 2017–2021, #2020-02155)
- Karolinska Institutet Stiftelser och Fonder (#249774, #13477, #38811, #182355, #270491, #291217, 2017–2021, #2020-02155)
This publication has 149 references indexed in Scilit:
- Altered expression patterns of complement factor H and miR‐146a genes in acute‐chronic phases in experimental autoimmune encephalomyelitis mouseJournal of Cellular Physiology, 2019
- Regulation and Immune Function of IL-272016
- A Method for Gene‐Based Pathway Analysis Using Genomewide Association Study Summary Statistics Reveals Nine New Type 1 Diabetes AssociationsGenetic Epidemiology, 2014
- Intra‐islet proliferation of cytotoxic T lymphocytes contributes to insulitis progressionEuropean Journal of Immunology, 2012
- Local expression of interleukin‐27 ameliorates collagen‐induced arthritisArthritis & Rheumatism, 2011
- Increased levels of interleukin-27 in patients with rheumatoid arthritisArthritis & Rheumatism, 2011
- IL‐27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cellsEuropean Journal of Immunology, 2010
- Interleukin‐27 inhibits human osteoclastogenesis by abrogating RANKL‐mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signalingArthritis & Rheumatism, 2010
- Interleukin 27 and viral hepatitisHepatology, 2009
- Cloning and Characterization of a Novel Class I Cytokine ReceptorBiochemical and Biophysical Research Communications, 1998